Automate Your Wheel Strategy on ADMA
With Tiblio's Option Bot, you can configure your own wheel strategy including ADMA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ADMA
- Rev/Share 1.9635
- Book/Share 1.6494
- PB 10.161
- Debt/Equity 0.2104
- CurrentRatio 5.3317
- ROIC 0.4628
- MktCap 3999455560.0
- FreeCF/Share 0.2737
- PFCF 60.5125
- PE 19.3721
- Debt/Assets 0.1501
- DivYield 0
- ROE 0.6178
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Wall Street Analysts Predict a 39.08% Upside in Adma Biologics (ADMA): Here's What You Should Know
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Adma Biologics (ADMA) points to a 39.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Read More
Will ADMA Biologics Stock Continue Its Momentum in 2025?
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
ADMA continues to maintain momentum in 2025 after its stupendous performance in 2024. Strong demand for Asceniv should fuel growth.
Read More
Should You Invest in Adma Biologics (ADMA) Based on Bullish Wall Street Views?
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
How Much Upside is Left in Adma Biologics (ADMA)? Wall Street Analysts Think 52.85%
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Block & Leviton is investigating ADMA Biologics for potential securities fraud. Investors who lost money in ADMA should contact the firm to learn more.
Read More
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 5, 2025, at 11:35 a.m. ET.
Read More
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
RAMSEY, N.J. and BOCA RATON, Fla.
Read More
Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Adma Biologics (ADMA) closed the most recent trading day at $16.07, moving -0.62% from the previous trading session.
Read More
Pharma Stock Poised to Bounce Off Support
Published: February 12, 2025 by: Schaeffers Research
Sentiment: Positive
Pharmaceutical concern ADMA Biologics Inc (NASDAQ:ADMA) has been consolidating above familiar pressure at the $16 region since mid-January.
Read More
About ADMA Biologics, Inc. (ADMA)
- IPO Date 2013-10-17
- Website https://www.admabiologics.com
- Industry Biotechnology
- CEO Adam S. Grossman
- Employees 685